tRNAs are emerging as both therapeutic targets and response biomarkers: engineered tRNAs inhibit hepatitis B virus replication, dual targeting of m7G tRNA modification and histone acetylation evokes osteosarcoma chemosensitization, and valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma. Arraystar's solution profiles the tRNA layer of drug discovery by sequencing, PCR arrays, and modification analysis.
The tRNA layer of drug discovery and therapy response
Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma [1]. Dual targeting of m7G tRNA modification and histone acetylation using carrier-free nano-epidrugs evokes osteosarcoma chemosensitization [2]. Anticodon engineered transfer RNA (tRNA(SUAG)) inhibits hepatitis B virus replication by promoting the degradation of core protein [3].
Arraystar's tRNA-targeted therapeutics solution profiles tRNA expression with tRNA-seq, the nrStar™ tRNA PCR Array, and pre-designed primer sets; quantifies tRNA modifications with LC-MS and modification sequencing; and profiles tRF/tiRNA responses with tRF&tiRNA-seq — supporting target validation, drug response, and resistance studies.
This solution profiles tRNA expression, tRNA modifications, and tRF/tiRNA populations in drug discovery research, using tRNA-seq, PCR arrays, LC-MS, and modification sequencing. It supports tRNA-targeted therapy development, drug resistance mechanisms, and therapy-response biomarker studies.
Drug discovery services — expression, modification, and fragment profiling
| Service Name | Profiling Layer | Price |
|---|---|---|
| nrStar™ tRNA PCR Array (H/M) | 185 human/mouse tRNAs for high-throughput monitoring | |
| Pre-designed tRNA Primer Sets | Individual mature tRNA quantification | |
| tRNA Sequencing | Comprehensive tRNA expression profiling | |
| tRNA Charging Seq | tRNA expression, modification & charging | |
| tRF&tiRNA Sequencing | tRF/tiRNA expression and therapy response |
Why choose Arraystar for drug discovery research
Profile the exact tRNAs and tRFs implicated in drug response and resistance.
tRNA PCR arrays and pre-designed primers screen many samples quickly.
LC-MS and modification sequencing quantify therapy-related tRNA modification changes.
Expression profiling supports engineered tRNA and therapeutic development.
Differential analyses and publication-quality graphics in every project.
Sequencing, arrays, and modification analysis in one drug discovery program.
tRNAs in therapy response and drug discovery
tRNAs are emerging as therapeutic targets and response biomarkers. Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma [1], and dual targeting of m7G tRNA modification and histone acetylation using carrier-free nano-epidrugs evokes osteosarcoma chemosensitization [2].
Anticodon engineered transfer RNA (tRNA(SUAG)) inhibits hepatitis B virus replication by promoting the degradation of core protein [3]. PAX translocations remodel mitochondrial metabolism through altered leucine usage in rhabdomyosarcoma [4].
m7G-modified tRNAs enhanced by METTL1 overexpression drive tumorigenesis in leukemia, glioblastoma, cholangiocarcinoma, and lung cancer [5], making tRNA modification pathways candidate therapeutic targets.
From drug-treated samples to tRNA-level therapeutic insights
RNA quality and quantity assessment before the project proceeds, with small-RNA-retaining purification.
tRNA-seq, the nrStar™ tRNA PCR Array, or pre-designed primers profile tRNA expression in treated versus control samples.
LC-MS, modification sequencing, and tRF&tiRNA-seq add modification and fragment layers.
Differential analyses with detailed annotations and publication-quality graphics.
Cross-reference tRNA changes with drug response, resistance, and clinical variables.
Deliverables for drug discovery projects
Every project includes focused bioinformatics with publication-quality graphics, enabling tRNA-level interpretation of drug response and resistance.
Drug discovery research applications
Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma (Nat Cell Biol, 2024).
Dual targeting of m7G tRNA modification and histone acetylation evokes osteosarcoma chemosensitization (Adv Mater, 2025).
Anticodon engineered transfer RNA inhibits hepatitis B virus replication by promoting core protein degradation (Adv Sci, 2025).
PAX translocations remodel mitochondrial metabolism through altered leucine usage in rhabdomyosarcoma (Cell, 2025).
m7G-modified tRNAs enhanced by METTL1 overexpression drive tumorigenesis in multiple malignancies (Mol Cell, 2021).
tRNA and tRF/tiRNA panels monitor therapy response across cohorts.
Method selection depends on your discovery stage and throughput needs
| Dimension | tRNA PCR Array / Primer Sets | tRNA Sequencing | tRNA Charging Seq | tRF&tiRNA Sequencing |
|---|---|---|---|---|
| Profiling scope | 185 tRNAs / individual tRNAs | Genome-wide tRNA expression | Expression, modification & charging | tRF/tiRNA expression |
| Best for | High-throughput cohort monitoring | Discovery of tRNA changes | Integrated multi-layer profiling | Fragment responses |
| Throughput | High (384-well, hours) | Low to moderate | Low to moderate | Low to moderate |
| Recommended RNA | > 5 µg | > 2 µg | > 5 µg | > 1 µg |
Official Arraystar sample submission requirements for drug discovery projects
Common questions about tRNA-targeted therapeutics & drug discovery
Key References for tRNA-Targeted Therapeutics & Drug Discovery Research
Arraystar profiles tRNA expression, modifications, and tRF/tiRNA responses for tRNA-targeted therapeutics and drug discovery — get a quote and a project timeline tailored to your study.